| RGLS Stock | | | USD 1.61 0.03 1.83% |
VP
Christopher JD is General VP of Regulus Therapeutics
| Age | 63 |
| Address | 4224 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 202 6300 |
| Web | https://www.regulusrx.com |
Regulus Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.4239) % which means that it has lost $0.4239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.7236) %, meaning that it created substantial loss on money invested by shareholders. Regulus Therapeutics' management efficiency ratios could be used to measure how well Regulus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -1.03 in 2024.
Return On Capital Employed is likely to drop to -1.47 in 2024. At this time, Regulus Therapeutics'
Total Assets are comparatively stable compared to the past year.
Non Current Assets Total is likely to gain to about 4.4
M in 2024, whereas
Other Current Assets are likely to drop slightly above 1.3
M in 2024.
Regulus Therapeutics currently holds 2.39
M in liabilities with Debt to Equity
(D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Regulus Therapeutics has a current ratio of 8.64, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Regulus Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | VP Age |
| Leah JD | Inhibrx | N/A |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Regulus Therapeutics (RGLS) is traded on NASDAQ Exchange in USA. It is located in 4224 Campus Point Court, San Diego, CA, United States, 92121 and employs 32 people. Regulus Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Regulus Therapeutics Leadership Team
Elected by the shareholders, the Regulus Therapeutics' board of directors comprises two types of representatives: Regulus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regulus. The board's role is to monitor Regulus Therapeutics' management team and ensure that shareholders' interests are well served. Regulus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regulus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, CEO Director | |
| MS MT, VP Operations | |
| MS MD, Senior Regulatory | |
| Christopher JD, General VP | |
| Crispina CPA, Chief Officer | |
| Denis Drygin, Chief Officer | |
| Firuz Shakoori, Head CMC | |
| MHS MD, Head President | |
| Daniel Penksa, Principal Accounting Officer, Controller | |
| Edmund Lee, Vice Medicine | |
Regulus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regulus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to
measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.